- 19 set.- 18:30

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial

Business Wire.
  • Cabometyx® in combination with Opdivo® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile
  • Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups
  • Patients treated with Cabometyx® in combination with Opdivo® reported significantly better health-related quality of life than those treated with sunitinib at most time points
  • These data have been selected for presentation during Presidential Symposium and featured in official Press Programme at European Society for Medical Oncology Virtual Congress 2020
- 18 set.- 20:11

Takeda presenta nuovi dati a dimostrazione dei progressi scientifici nella lotta al carcinoma polmonare nell'ambito del Congresso virtuale dell'ESMO

Business Wire.

Risultati importanti dalle analisi secondarie dello studio di fase 3 ALTA 1L supportano ulteriormente la solida efficacia intracranica di ALUNBRIG e il miglioramento della qualità della vita nel trattamento di prima linea di NSCLC ALK+

I dati positivi del follow-up a 10 mesi dallo studio di fase 1/2 confermano i risultati precedentemente riportati su mobocertinib nei pazienti con NSCLC metastatico con mutazioni inserzionali dell'esone 20 dell'EGFR

- 18 set.- 20:06

Incyte annuncia risultati incoraggianti dallo studio clinico di fase 2 su retifanlimab (INCMGA0012) in pazienti con carcinoma a cellule squamose del canale anale in fase avanzata precedentemente trattati

Business Wire.
  • Le risposte confermate da un esame centrale indipendente comprendono 1 risposta completa, 12 risposte parziali e 33 risposte di malattia stabile per un tasso di risposta oggettivo pari al 14% e un controllo della malattia pari al 49%
  • Le risposte sono state osservate indipendentemente dallo status del PD-L1, dalla presenza di metastasi epatiche o dallo stadio dell'HIV+
  • La presentazione è disponibile on-demand nell'ambito del Congresso virtuale ESMO 2020
  • POD1UM-303/InterAACT 2, uno studio clinico di fase 3 volto a valutare retifanlimab addizionato a chemioterapia in pazienti con carcinoma a cellule squamose del canale anale non operabile localmente ricorrente o metastatico è attualmente aperto e in fase di arruolamento dei pazienti.
- 18 set.- 12:00

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Business Wire.
  • Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%
  • Responses were observed regardless of PD-L1 status, presence of liver metastases or HIV+ status
  • Presentation is available on-demand as part of the ESMO Virtual Congress 2020
  • POD1UM-303/InterAACT 2, a Phase 3 trial evaluating retifanlimab plus chemotherapy in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal is now open and recruiting patients.
- 18 set.- 09:30

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure

Business Wire.
  • Sigfox, the global 0G network and cloud provider for industrial data, announces a new strategic alliance with Cube Infrastructure Managers.
  • Cube Infrastructure Managers brings together the Sigfox 0G network operators in Germany, Austria, Switzerland and Liechtenstein, through the acquisition of a majority stake in Heliot Europe and the acquisition of Sigfox Germany.
  • This transaction will accelerate the deployment of IoT infrastructure, which is essential to the competitiveness and sustainable development of the European economy.
- 18 set.- 07:00

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months

Business Wire.
  • Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs
  • These results show no new safety signals associated with this increased dose regimen, potentially delaying the need for additional, more toxic second-line therapies
  • The incidence of NETs is increasing, and are now among the fastest growing class of cancers worldwide, accounting for around 2% of all cancers1

 

- 18 set.- 07:00

Vifor Pharma Group Announces Successful Sale of OM Pharma

Business Wire.
  • Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435
  • In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500
  • Closure of the transaction is expected within 30 days
  • Divestment strengthens Vifor Pharma’s focus on becoming the global leader in iron deficiency, nephrology and cardio-renal therapies

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate

Criptovalute news


Modifica consenso Cookie